Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the prevalence of hirsutism in women and highlights that many cases exhibit normal androgen levels, suggesting a need for broader diagnostic approaches.

This case study describes a severe instance of iatrogenic Cushing's syndrome induced by gamma-hydroxybutyric acid, exacerbated by combined use of betamethasone and anabolic steroids, in an HIV-positive patient on cobicistat-containing therapy.

Using finasteride for hair loss or prostate issues does not significantly raise the risk of erectile dysfunction.

This review discusses the cosmetic and health implications of hirsutism and highlights its potential link to serious underlying disorders, but it presents no new clinical findings.

This review covers androgenetic alopecia's epidemiology, pathogenesis, current management options, and research trends, concluding that no definitive cure exists despite extensive interest and ongoing genetic research efforts.

In this case report, a patient with subclinical hypothyroidism exhibited a significant reduction in TSH levels after four months of ayurvedic treatment, but levels slightly increased afterward.

This article discusses androgenetic alopecia in men and reports that finasteride at 1 mg/day for 24 months is generally well tolerated and may effectively inhibit hair loss.

This review discusses the role of DHEA in intracrinology, highlighting its impact on breast and prostate cancer treatment and potential as a menopause therapy, but reports no new research findings.

This review discusses the neurobiology of sexual function and reports no new results; the authors cover multiple endocrine and neurotransmitter influences on sexual desire, arousal, and orgasm stages.

This review discusses the increasing prevalence of erectile dysfunction in young men and emphasizes the importance of identifying specific causes for effective management, reporting no new clinical results.

This review analyzes how the pharmaceutical industry's emphasis on lifestyle drugs and marketing practices leads to the integration of pharmaceuticals into everyday life, with a domestic focus and view of drugs as quick solutions.

This article discusses treatment options for androgenetic alopecia, noting that medical interventions like finasteride and minoxidil can halt and partially reverse hair loss in mild to moderate cases, especially when combined with surgery.

This article reviews how various hormones may affect female sexual function and provides recommendations for diagnosing and treating endocrinologic sexual difficulties, but it reports no new clinical results.

This review discusses the safety of testosterone therapy for postmenopausal women and concludes that, aside from hirsutism and acne, it appears safe at physiological doses for several years, though more long-term studies are needed.

This review discusses phytotherapy options for managing benign prostatic hyperplasia, noting some herbal agents show promise in trials for mild-moderate symptoms but more evidence is needed for others.

Antiandrogens, particularly flutamide and CPA, are most effective for treating hirsutism, with long-term use needed for best results.

This study examined different polymersome systems for topical finasteride delivery and found that chitosan-decorated C7 polymersomes may enhance skin retention and provide controlled drug release compared to non-decorated systems in laboratory settings.

This review concludes that antiandrogens with ovarian suppression may significantly improve hirsutism and androgenetic alopecia in women with PCOS, but treatment needs to continue unless the underlying PCOS cause is addressed.

This article reviews the psychological, social, and biological impacts of polycystic ovary syndrome on women of reproductive age and reports no new experimental results.

This study found that long-term flutamide treatment reduced hair loss in women with female pattern hair loss, but liver-related dropouts were minimized at a very low dose of 62.5 mg/day.

This study found that finasteride significantly reduced hirsutism in women with idiopathic hirsutism or polycystic ovary syndrome over six months, suggesting its potential effectiveness for this condition.

This review refutes several myths about testosterone therapy in women and suggests that testosterone is beneficial for both physical and mental health, though its safety in women continues to be researched.

This review discusses the interplay between epilepsy and reproductive endocrine disorders, examining the factors involved and emphasizing the importance of monitoring but reports no new research findings.

This study found that in Japanese male patients with androgenetic alopecia, dutasteride 0.5 mg daily over 52 weeks was associated with improvements in hair growth and appearance, with reported adverse events mostly mild.

This review discusses hair transplant techniques for female pattern hair loss and reports no new clinical results; it highlights the benefits of transplants combined with various treatments for improved hair density and styling options.

This article reviews current osteoporosis treatments, focusing on the potential of selective androgen receptor modulators and other agents to enhance bone formation, but provides no new clinical data.

In this preliminary study, women with facial hirsutism treated with topically applied finasteride cream showed a significant decrease in hair growth and thickness compared to placebo, without adverse effects.

This review summarizes preclinical and clinical information on herbal products for hair loss treatment, highlighting their mechanisms, follicular penetration, and potential side effects, suggesting they may offer alternatives to synthetic drugs with fewer side effects.

This study found that finasteride was associated with more reproductive adverse effects, including sexual dysfunction in men and fetal harm in women, compared to minoxidil in reported alopecia cases.

This review discusses treatment options for hirsutism in women of childbearing age, focusing on the use of contraceptives, CPA, spironolactone, and third-line therapies, and reports no clinical results.